Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)
About
The purpose of this Program Announcement with Special Receipt, Referral, and/or Review Considerations (PAR) is to solicit applications to access stored blood plasma, blood serum, and extracted DNA from the All of Us Research Program supported Biobank to advance the program's mission of accelerating health research and medical breakthroughs, enabling individualized prevention, treatment, and care for all of us. All of Us partnered research studies are collaborative initiatives funded by a study sponsor external to All of Us to collect and add new data to the All of Us Researcher Workbench in accordance with All of Us" best practices. All of Us partnered research studies are open to the broad scientific community and require investigators to apply for and receive an X01 award under this announcement. This will enable longitudinal follow‐up and repeat sampling, and provide multiomic data (genomics, proteomics, metabolomics, and other high‐dimensional molecular profiles), integrated clinical, environmental, and life‐course data, infrastructure designed to support future clinical‐trial recruitment, and public‐private partnership pathways. This opportunity will enable researchers to conduct assays to evaluate associations between newly collected and existing All of Us data and add new data to the All of Us dataset for broad use by the research community. High-priority areas for biospecimen analyses may include, but are not limited to, large scale projects that propose integrated multi.
The Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed) grant program invites researchers and scientific institutions to access valuable stored biospecimens from the All of Us Research Program Biobank. This initiative supports collaborative, externally-funded research studies designed to advance health research and enable personalized medicine breakthroughs. Researchers can access blood plasma, blood serum, and extracted DNA samples while conducting new analyses and collecting additional data to contribute to the All of Us Researcher Workbench. The program is ideal for investigators seeking to perform large-scale, multi-omic analyses including genomics, proteomics, metabolomics, and other high-dimensional molecular profiling. Eligible applicants receive X01 awards to support longitudinal follow-up studies, repeat sampling initiatives, and integrated clinical and environmental data collection. This opportunity enables researchers to evaluate associations between newly collected and existing All of Us data, with results benefiting the broader scientific community. The program supports public-private partnerships and infrastructure designed to facilitate future clinical trial recruitment. Both domestic and international organizations, including foreign components of U.S. institutions, are eligible to apply, making this a globally accessible funding opportunity for advancing precision health research.
Funding Facts
● Applications openDeadline
March 1, 2027
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Not specified—contact program for details
Deadline
2027-03-01
Grant Type
federal
Application Cycle
Annual with March 1, 2027 deadline
Best For
Research institutions, academic centers, and external study sponsors conducting biospecimen analyses and partnered health research studies
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Frequently Asked Questions
Who is eligible for Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)?
Eligible applicants include both domestic U.S. entities and non-domestic (foreign) organizations. Non-U.S. components of U.S. organizations and foreign collaborations are also eligible. Clinical trial proposals are not permitted under this announcement. Investigators must apply for and receive an X01 award. For comprehensive eligibility requirements, refer to Section III of the Notice of Funding Opportunity (NOFO) or visit the official NIH/All of Us Research Program website.
How much funding does Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed) provide?
Specific funding amounts are not specified in the available program details. Award amounts may vary depending on the research proposal and scope. Contact the All of Us Research Program or the issuing NIH institute/center directly for current funding levels, or consult the official NOFO for detailed budget information.
How do I apply for Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)?
Applications are submitted through the NIH electronic submission system (eRA Commons/ERA). Investigators must prepare a complete research application proposing biospecimen analyses using All of Us Biobank resources and submit by the deadline (March 1, 2027). Detailed application instructions, required forms, and submission guidelines are available in the official NOFO. Visit the NIH grants website or All of Us Research Program portal for current application procedures and support.
What can Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed) funding be used for?
Funding supports partnered research studies that access All of Us Biobank biospecimens to conduct new analyses and collect additional data. Eligible uses include multi-omic analyses (genomics, proteomics, metabolomics), longitudinal follow-up studies, repeat biospecimen sampling, assay development, integration of clinical and environmental data, and infrastructure supporting future clinical trial recruitment. Large-scale projects proposing integrated multi-omic analyses are prioritized. Funding enables researchers to add new data to the All of Us Researcher Workbench for broad scientific community use.
Last updated: July 5, 2026